


PHARMACEUTICAL 2022

Cellectar Biosciences Inc. Rank 358 of 475







## Cellectar Biosciences Inc. Rank 358 of 475

The relative strengths and weaknesses of Cellectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cellectar Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of Cellectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 208% points.

The company's Economic Capital Ratio, given in the ranking table, is -298%, being 21% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	36,571
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,990
Liabilities, Non-Current	166
Other Assets	286
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	8.9
Property and Equipment	344
Research and Development	17,586
Revenues	0
Selling, General and Administrative Expense	6,545

Output Variable	Value in 1000 USD
Assets	37,202
Liabilities	4,157
Expenses	24,131
Stockholders Equity	33,045
Net Income	-24,122
Comprehensive Net Income	-24,122
Economic Capital Ratio	-298%

